Rigel Pharmaceuticals
Research Rigel Pharmaceuticals (RIGL) on Bullrun: market cap USD 872.07M, P/E 2.9. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRIGL
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 872.07M
- P/E2.9
- Financial periodQ2 2026
- RevenueUSD 78.70M
- Net incomeUSD 17.29M
- Free cash flow-USD 39.69M
- Gross margin89.2%
Valuation Snapshot
latest market cap is USD 872.07M; P/E is 2.9.
Peer valuation comparison
Latest P/E is 2.86x versus a Healthcare sector median of 24.46x (88.3% below).
Latest P/E is 2.86x versus a United States median of 24.87x (88.5% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 294.28M | USD 367.02M | USD 75.66M | 93.3% | 19.48 | USD 40.58M | USD 52.50M | USD 391.48M |
| FY2024 | USD 179.28M | USD 17.49M | USD 31.08M | 89.6% | 0.99 | USD 56.75M | USD 60.00M | USD 3.29M |
| FY2023 | USD 116.88M | -USD 25.09M | n/a | 93.9% | -1.44 | USD 32.79M | USD 60.00M | -USD 28.64M |
| FY2022 | USD 120.24M | -USD 58.57M | -USD 74.21M | 98.5% | -3.44 | USD 24.46M | USD 40.00M | -USD 13.62M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 872.07M | 2.9 | n/a | n/a |
| 2025 | 2025-12-31 | USD 784.26M | 2.3 | n/a | n/a |
| 2024 | 2024-12-31 | USD 297.89M | 17.3 | n/a | n/a |
| 2023 | 2023-12-29 | USD 252.84M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 259.25M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 454.75M | n/a | n/a | n/a |
About Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Rigel Pharmaceuticals's market cap?
Rigel Pharmaceuticals's market capitalization is USD 872.07M.
What is Rigel Pharmaceuticals's P/E ratio?
Rigel Pharmaceuticals's price-to-earnings (P/E) ratio is 2.9.
What does Rigel Pharmaceuticals do?
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.